Your browser is no longer supported. Please, upgrade your browser.
MYL Mylan, Inc. weekly Stock Chart
MYL [NASD]
Mylan, Inc.
IndexS&P 500 P/E135.17 EPS (ttm)0.12 Insider Own0.20% Shs Outstand516.40M Perf Week1.52%
Market Cap8.57B Forward P/E3.61 EPS next Y4.54 Insider Trans0.00% Shs Float511.58M Perf Month2.99%
Income62.60M PEG53.01 EPS next Q0.98 Inst Own89.00% Short Float6.26% Perf Quarter-6.92%
Sales11.62B P/S0.74 EPS this Y-95.00% Inst Trans0.04% Short Ratio5.29 Perf Half Y-28.17%
Book/sh21.81 P/B0.75 EPS next Y3.85% ROA0.20% Target Price21.97 Perf Year-14.33%
Cash/sh1.23 P/C13.35 EPS next 5Y2.55% ROE0.50% 52W Range12.75 - 23.11 Perf YTD-18.63%
Dividend- P/FCF4.44 EPS past 5Y-58.00% ROI2.30% 52W High-29.23% Beta1.55
Dividend %- Quick Ratio0.80 Sales past 5Y8.30% Gross Margin40.00% 52W Low28.27% ATR0.61
Employees35000 Current Ratio1.30 Sales Q/Q5.00% Oper. Margin7.40% RSI (14)48.03 Volatility4.59% 3.50%
OptionableYes Debt/Eq1.12 EPS Q/Q182.90% Profit Margin0.50% Rel Volume0.63 Prev Close16.42
ShortableYes LT Debt/Eq0.99 EarningsAug 06 BMO Payout0.00% Avg Volume6.05M Price16.35
Recom2.20 SMA20-0.53% SMA50-1.23% SMA200-7.74% Volume3,799,090 Change-0.40%
Jan-27-20Downgrade SVB Leerink Outperform → Mkt Perform $24
Jan-09-20Initiated Piper Sandler Neutral $21
Nov-07-19Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-05-19Downgrade CFRA Hold → Sell
Jul-19-19Initiated Wolfe Research Outperform
Jun-11-19Initiated Barclays Overweight $26
May-08-19Downgrade Wells Fargo Outperform → Market Perform $33 → $22
Mar-20-19Initiated SunTrust Buy $35
Mar-07-19Resumed UBS Neutral $31
Mar-06-19Upgrade Morgan Stanley Equal-Weight → Overweight $35
Feb-27-19Downgrade Bernstein Outperform → Mkt Perform $33
Jan-23-19Downgrade UBS Buy → Neutral
Nov-15-18Upgrade Argus Hold → Buy
Nov-06-18Upgrade BofA/Merrill Neutral → Buy
Oct-09-18Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-05-18Downgrade Mizuho Buy → Neutral
Aug-24-18Upgrade Evercore ISI In-line → Outperform
Aug-13-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Apr-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Mar-15-18Reiterated Mizuho Buy $45 → $51
Aug-06-20 01:24PM  
07:45AM  
06:56AM  
06:46AM  
06:41AM  
06:30AM  
Aug-04-20 04:59PM  
Aug-02-20 10:05AM  
Jul-30-20 12:33PM  
11:00AM  
Jul-29-20 12:10PM  
Jul-28-20 08:59AM  
Jul-27-20 10:00AM  
10:00AM  
Jul-22-20 07:30AM  
05:59AM  
05:50AM  
Jul-21-20 06:40PM  
Jul-20-20 08:00AM  
Jul-18-20 01:45PM  
Jul-17-20 09:00AM  
Jul-16-20 12:29AM  
Jul-15-20 05:55PM  
Jul-14-20 09:00AM  
Jul-10-20 10:24AM  
09:00AM  
Jul-09-20 07:15PM  
07:15PM  
05:45PM  
08:30AM  
06:30AM  
Jul-08-20 05:50PM  
08:59AM  
Jul-07-20 07:03PM  
04:44PM  
12:49PM  
11:35AM  
10:25AM  
06:14AM  
Jul-06-20 04:20PM  
03:39PM  
01:05PM  
12:12PM  
07:14AM  
07:14AM  
07:07AM  
06:00AM  
04:16AM  
01:30AM  
Jul-04-20 04:40PM  
Jul-03-20 12:27PM  
11:00AM  
Jul-02-20 04:51PM  
02:50PM  
02:40PM  
01:30PM  
01:00PM  
Jul-01-20 09:37PM  
08:09PM  
04:25PM  
03:48PM  
01:40PM  
01:00PM  
11:40AM  
11:00AM  
Jun-30-20 09:50PM  
09:30PM  
07:55PM  
07:50PM  
11:40AM  
11:33AM  
11:00AM  
10:30AM  
10:00AM  
Jun-29-20 06:35PM  
05:25PM  
03:53PM  
09:31AM  
Jun-26-20 02:04PM  
Jun-23-20 03:48PM  
Jun-21-20 07:26AM  
Jun-19-20 06:04PM  
04:48PM  
11:00AM  
10:22AM  
09:34AM  
07:41AM  
Jun-18-20 04:21PM  
04:04PM  
04:00PM  
02:19PM  
01:31PM  
12:24PM  
11:55AM  
11:08AM  
11:02AM  
10:55AM  
06:59AM  
06:45AM  
Jun-17-20 09:13AM  
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Parks Kenneth ScottChief Financial OfficerMar 03Option Exercise0.0013,945039,476Mar 04 06:33 PM
Malik RajivPresidentMar 03Option Exercise0.0043,3830283,195Mar 04 06:41 PM
Mauro AnthonyChief Commercial OfficerMar 03Option Exercise0.0019,3670125,321Mar 04 06:31 PM
BRESCH HEATHER MChief Executive OfficerMar 03Option Exercise0.0070,4960302,999Mar 04 06:38 PM
Campbell PaulSee RemarksMar 03Option Exercise0.002200583Mar 04 06:32 PM
Campbell PaulSee RemarksMar 03Option Exercise0.002,906031,238Mar 04 06:32 PM
Campbell PaulSee RemarksMar 02Option Exercise0.005510494Mar 04 06:32 PM
Campbell PaulSee RemarksMar 02Option Exercise0.006,109030,550Mar 04 06:32 PM
DIMICK NEIL FDirectorMar 02Option Exercise0.006,011053,017Mar 04 06:32 PM
Vollebregt Sjoerd SDirectorMar 02Option Exercise0.006,011048,269Mar 04 06:33 PM
HIGGINS MELINA EDirectorMar 02Option Exercise0.006,011039,131Mar 04 06:30 PM
Cindrich Robert JDirectorMar 02Option Exercise0.006,011027,479Mar 04 06:31 PM
BRESCH HEATHER MChief Executive OfficerMar 02Option Exercise0.0073,2130264,089Mar 04 06:38 PM
van der Meer Mohr PaulineDirectorMar 02Option Exercise0.006,01108,695Mar 04 06:37 PM
Lyons Dillon JoEllenDirectorMar 02Option Exercise0.006,011018,039Mar 04 06:35 PM
MARK RICHARD ADirectorMar 02Option Exercise0.009,007013,007Mar 04 06:35 PM
KORMAN HARRYDirectorMar 02Option Exercise0.006,011028,945Mar 04 06:35 PM
Mauro AnthonyChief Commercial OfficerMar 02Option Exercise0.0021,6460115,119Mar 04 06:31 PM
Malik RajivPresidentMar 02Option Exercise0.0048,1610260,076Mar 04 06:41 PM
Parks Kenneth ScottChief Financial OfficerMar 02Option Exercise0.0021,646034,082Mar 04 06:33 PM
PARRISH MARK WDirectorMar 02Option Exercise0.006,011045,795Mar 04 06:48 PM
VANDERVEEN RANDALL LDirectorMar 02Option Exercise0.006,011050,217Mar 04 06:44 PM
Campbell PaulSee RemarksFeb 05Sale23.0011,611267,05325,413Feb 07 06:00 PM
HIGGINS MELINA EDirectorAug 15Buy17.6820,000353,54833,120Aug 19 07:29 PM
Vollebregt Sjoerd SDirectorAug 14Buy18.8124,000451,43942,258Aug 15 06:30 PM
Vollebregt Sjoerd SDirectorAug 13Buy19.1110,000191,10018,258Aug 15 06:30 PM